What a biosimilar is
The European Medicines Agency (EMA) defines a biosimilar as a biological medicine that is highly similar to another biological medicine already approved in the EU. That earlier medicine is called the reference medicine.
How biosimilars are approved in the EU
A biosimilar has to show, through comprehensive comparability studies with its reference medicine, that there are no clinically meaningful differences between the two. The EU approved its first biosimilar in 2006.
Interchangeability
In a joint statement, EMA and the Heads of Medicines Agencies (HMA) set out that once a biosimilar is approved in the EU it is interchangeable. They add that interchange should take place only after careful consideration of the approved conditions of use. The statement was first published in September 2022 and updated in April 2023. Outside the EU, follow the position of your own regulator.
Traceability
The EU guide on biosimilars for healthcare professionals explains that biological medicines have to be distinguished by their trade name and batch number. Recording both for every delivery keeps each product traceable.
WHO and India
WHO's current guideline is the Guidelines on evaluation of biosimilars (Technical Report Series No. 1043, Annex 3, 2022), which replaced Annex 2 of Technical Report Series No. 977. WHO now uses the term "biosimilar" rather than "similar biotherapeutic product".
In India, the Department of Biotechnology and CDSCO published the Guidelines on Similar Biologics, the regulatory requirements for marketing authorisation in India, in 2016, and Indian regulation uses the term "similar biologics". A revised version, released in 2025 with an invitation for comments, states that it replaces the 2016 guideline and that "similar biologics" and "biosimilar" mean the same thing.
What to check before you import a biosimilar
- The product is authorised in your country, or your regulator allows the import route you plan to use
- Which reference medicine it was compared with, and the product information approved in your country
- The storage conditions in section 6.4 of the product information, and how the temperature is kept in transit (see our cold-chain guide)
- That the trade name and batch number are recorded when the goods arrive
- Your regulator's position on interchange and substitution
Biosimilars from Bio Bridge Pharma
We supply biosimilars and other biological medicines alongside originator brands. See Biosimilars & Biologics, or the reference pages for filgrastim, epoetin alfa, enoxaparin, trastuzumab, rituximab and adalimumab. Tell us the product, strength and destination country, and we confirm the registration route and import licence before making an offer.
Send EnquirySources
- European Medicines Agency, Biosimilar medicines: overview: ema.europa.eu
- European Medicines Agency and European Commission, Biosimilars in the EU: information guide for healthcare professionals (traceability): ema.europa.eu
- EMA and HMA, Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU (EMA/627319/2022): ema.europa.eu
- World Health Organization, Guidelines on evaluation of biosimilars (Technical Report Series No. 1043, Annex 3): who.int
- World Health Organization, Biosimilars: who.int
- Central Drugs Standard Control Organisation and Department of Biotechnology, Guidelines on Similar Biologics, 2025 revision: cdsco.gov.in
- Central Drugs Standard Control Organisation, guidance document citing the 2016 Guidelines on Similar Biologics: cdsco.gov.in